Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Three cases of metastatic adenocarcinoma of the male breast from prostatic carcinoma are added to the 15 well-documented cases reported in the literature. These 15 cases had received estrogen therapy for prostatic cancer and gynecomastia developed; 14 had clinically palpable breast nodules containing adenocarcinoma. Our 3 cases also received estrogen therapy but differed in that gynecomastia developed in only 1 patient clinically, and diagnoses were made at autopsy with no clinical symptoms related to breast metastases. Moreover, 1 cases also showed remarkable florid lactation-like changes of the breast almost indistinguishable morphologically from that seen in the female breast during pregnancy. The histopathologic differential diagnosis of metastatic prostatic carcinoma of the breast from primary cancer of the male breast is stressed. Its importance is obvious because of the differences in clinical treatment and prognosis. Microscopically, the differential points consist of duct hypertrophy and periductal fibrosis (gynecomastia), absence of any ductal involvement by carcinoma cells, frequent presence of cancer cells in lymphatics and vascular channels, morphologic similarity between the cancers in the breast and prostate, and finally, the usual presence of acid phosphatase in the tumors of the prostate and breast.
 ...
PMID:Metastatic prostatic adenocarcinoma of male breast. 67 36

Sixteen patients with prostatic carcinoma were treated with 200 mg of Cyproterone acetate daily. No other kind of hormonal treatment was administered. Increasing skeletal metastases were observed in 6 patients, whereas significant reduction of metastases took place in 2 patients. Objective relief of stranguria was observed only in 3 patients. The amount of residual urine increased in 3 patients and was reduced in 5. In about one third of the patients, the prostate gland became smaller and softer. The acidic phosphatases decreased from pathological to normal values in 7 patients. There were no observed hepatic, renal or haemotological side-effects. However, serious cardio-vascular complications occurred in 6 patients, while arterial hypertension developed in 4. It is suggested that Cyproterone acetate cannot be recommended as the only kind of hormonal treatment of prostatic cancer.
 ...
PMID:Treatment of prostatic carcinoma with cyproterone acetate. 69 35

The immune competence of 65 patients with prostatic cancer was evaluated by 2 in vivo and 2 in vitro tests to study the contribution of host factors to the progress of the disease. Patients with benign prostatic hypertrophy served as controls. Our results indicate that the delayed skin hypersensitivity response to common microbial recall antigens (streptokinase/streptodornase, purified protein derivative, dermatophytin 0 and dermatophytin) is unaltered in advanced stages of malignancy. The ability to be sensitized by dinitrochlorobenzene declines significantly in patients with metastatic disease. Blastogenic response of peripheral blood lymphocytes to phytohemagglutinin stimulation is not depressed in late stages of malignancy, although in the circulating T cells per cent and absolute values are somewhat lower in patients with metastases. Herein we show that immune competence (measured by the 4 tests) of patients with prostatic carcinoma does not decrease markedly even in the late stages of the disease. Primary sensitization to dinitrochlorobenzene is the only test showing a decline in responsiveness related to the tumor stage.
 ...
PMID:Cell-mediated immune competence in patients with prostatic carcinoma. 70 65

Results of cryosurgery in the manipulation of prostate cancer in a rabbit animal model is discussed. Clinical application of cryosurgery in the treatment of prostate cancer in man and its effect on metastases is presented.
 ...
PMID:Cryosurgery in prostate carcinoma: clinical evidence of immunostimulation of host versus tumor. 74 95

130 serum specimens were evaluated. None of 24 serum specimens from patients with prostatic cancer yielded precipitation of haemagglutination reactions with extracts of normal human prostatic tissue or with preparations of prostatic fluid. In 1 of 5 patients from whom autologous prostatic tissue was available, precipitation was observed. By indirect immunofluroescence 13 (54%) patients with prostatic cancer possessed antibodies reactive with the cytoplasmic membrane (intercellular area?) of primate prostatic secretory epithelium. Membranous autoantibodies were observed in 2 patients from whom autologous tissue was available as substrate. Antibodies to nuclei were observed but these have been considered in view of their ubiquitous nature, as perhaps being representative of non-specific indicators of other immunologic aberrations. In contrast, only 11 (10%) of 106 patients with other than prostatic cancer possessed membranous antibodies; of these, 11 (73%) possessed a genito-urinary disorder (5 benign prostatic hypertrophy, considered by some as predisposing to prostatic cancer and 3 carcinoma of the bladder). While not possessing sufficient specificity for diagnosis, the high incidence of this antibody, 92% positive in patients with advanced disease (Stage III), suggests it may be useful as a prognostic index of patients with metastatic disease.
 ...
PMID:Serum antibody in patients with prostatic cancer. 82 78

40 patients with inoperable, histologically proved carcinoma of the prostate were treated with estramustine phosphate. 35 patients had progressive, symptomatic, metastatic disease unresponsive to conventional oestrogens and/or castration Estramustine phosphate was given intravenously initially at a dose of 150 mg/day increasing to 300 mg/day. After 3 weeks or more oral therapy was substituted in 23 patients at a dose of 560 mg/day. Of 23 evaluable patients given the drug by both routes, 17 died after a mean treatment period of 12.5 months and 6 are alive and well after a mean treatment period of 27.7 months. The cause of death in 2 patients was probably, and in a third certainly, due to myocardial infarction. The other 31 deaths were due to carcinoma of the prostate. 18 patients showed transient toxic side-effects. No haematological abnormalities were found during treatment. An attempt at active treatment with estramustine phosphate in patients with prostatic cancer is justified when the disease is resistant to treatment with conventional oestrogens.
 ...
PMID:Treatment of advanced carcinoma of the prostate with estramustine phosphate. 83 52

The effect of sera from 256 human cancer patients on the human antibody-dependent cellular cytotoxicity (ADCC) assay was studied. The cancer sera were compared to normal sera for their ability to alter the effector function of lymphocytes following 30 minutes' treatment at 37 degrees C. Even with this brief treatment, 74% of the 256 cancer sera inhibited effector activity. In most instances this inhibition was greater in patients with metastatic disease than in those without. Patients with colon and prostate cancer showed a statistically significant increase in inhibition among patients with disseminated disease (P less than 0.02 and P less than 0.01, respectively). An opposite effect was noted only in melanomas. It is suggested that the inhibition of the effector function in ADCC is a potential in vitro measure of the immunologic status of cancer patients.
 ...
PMID:Inhibition of effector cell function in human antibody-dependent cellular cytotoxicity by sera from cancer patients. 85 35

The authors have evaluated a new kinetic acid phosphatase method in which the substrate is alpha-naphthyl phosphate. The original claim that this substrate was highly specific for the prostatic isozyme has been strongly challenged. Therefore, large numbers of patients in the following groupings were included in the evaluation: 52 urology clinic patients, 17 patients with uremia, 11 patients with multiple myeloma and 231 patients who had undergone prostatic biopsies. Two hundred seventy of these patients were found to be free of prostatic cancer. Of these, seven had acid phosphatase values above the upper limit of normal. Five of these seven patients had diagnoses of fibromuscular glandular hyperplasia. One was a woman who had multiple myeloma, and one was a uremic patient. Fifteen of 17 patients who had metastatic cancer of the prostate had elevated acid phosphatase activities, whereas one of 24 patients who had cancer of the prostate but no evidence of metastases had an elevated value.
 ...
PMID:An evaluation of a kinetic acid phosphatase method. 86 5

150 cases of prostate cancer treated with estrogens at the Urology clinic of the Hotel-Dieu from 1963 to 1974 are presented. The men ranged in age from 50 to 91; the majority were 60-69 years. Their clinical stages were 29% Stage 1, no perceptible mass; 43% Stage 2, nodule felt on rectal exam; 13% Stage 3, tumor extended outside the prostate but not metastases, normal prostatic phosphatases; and 15% Stage 4, elevated prostatic phasphatases and metastases. Diagnosis was by urinary symptoms in Stage 2 or above, rectal palpation, and puncture biopsy under local anesthesia. Estrogen treatment consisted of diethylstilbestrol, stilbelstrol diphosphate or TACE (Chlorotraianisene), or estradiol. Estrogen side effects were loss of libido after 1 month, gynecomastia, and nausea. Other treatments included prostatectomy in Stages 1 and 2, cobalt in 5 cases, castration in 3 cases, 1 endo-uretral resection, and 1 hypophysectomy. 50% died in 1 year and 16% were lost to follow up and presumed dead in 1 year; the mean survival of the others was 3 years. Estrogen therapy improved symptoms and reversed tumor growth temporarily in hormone-dependent cancers, but these tumors all escape hormone control eventually.
 ...
PMID:[Course of prostate cancer under estrogen therapy]. 87 31

On 170 patients with histologically proven carcinoma of the prostate scintigraphic studies of the skeleton using gamma camera and follow-up examinations were performed and compared with x-ray as well as serum alkaline and acid phosphatase. Osseous metastases in 47% had no radiological evidence and were only scintigraphically detectable. Positive scans were registered in 48% of the patients with prostatic cancer, 20% of them were positive due to metastases and 28% were false positive caused by osteoarthrotic and arthritic changes, sporadically by post-traumatic lesions and in 3 cases by Paget's disease. At the time of the initial diagnosis of prostatic cancer 21% of 159 patients studied scintigraphically had radiological or scan evidence of osseous metastases. Analyses corresponding stages of tumor revealed an unequivocal dependance of the frequency of metastases upon the extent of the primary tumor. The successful treatment is characterized by the decreased uptake of radioactivity primarily accumulated in skeletal metastases.
 ...
PMID:[Diagnosis of skeletal metastases in prostatic cancer using gamma camera (author's transl)]. 87 70


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>